8-K: Gossamer Bio Receives Nasdaq Delisting Notice Due to Low Share Price

Gossamer Bio has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement for continued listing.

Summary

• Gossamer Bio received a notice from Nasdaq on May 22, 2024, stating that its common stock did not maintain a minimum bid price of $1.00 per share for 30 consecutive business days between April 10, 2024, and May 21, 2024.
• This failure to meet the minimum bid price requirement puts the company at risk of being delisted from the Nasdaq Global Select Market.
• Gossamer Bio has 180 calendar days, until November 18, 2024, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If the company fails to regain compliance within this period, it may be eligible for an additional 180-day compliance period by transferring its listing to the Nasdaq Capital Market and meeting other listing requirements.
• The company may consider options such as a reverse stock split to regain compliance, but there is no guarantee that it will be successful.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The risk of delisting is a significant concern for investors.

Negatives

• The company's stock price has fallen below the minimum bid price requirement of $1.00 per share.
• Gossamer Bio is at risk of being delisted from the Nasdaq Global Select Market.
• There is no guarantee that the company will be able to regain compliance with Nasdaq listing rules.

Risks

• The company faces the risk of delisting from the Nasdaq Global Select Market if it cannot regain compliance with the minimum bid price requirement.
• A reverse stock split may be necessary, which could negatively impact shareholder value.
• There is no assurance that the company will be able to successfully appeal a delisting determination.

Future Outlook

The company intends to monitor its stock price and consider options to regain compliance, but there is no guarantee of success.

Management Comments

• The Company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement.

Industry Context

Delisting notices are not uncommon for companies that experience prolonged periods of low stock prices, reflecting broader market conditions and investor sentiment towards the company's performance and prospects.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face challenges in maintaining stock prices above the minimum bid price requirement.
• Companies like Cassava Sciences and Ocugen have also faced similar delisting risks due to stock price volatility.
• The ability to regain compliance often depends on positive clinical trial results, regulatory approvals, or significant financial milestones.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation may be negatively impacted.

Next Steps

• The company will monitor its stock price.
• The company may consider options to regain compliance, such as a reverse stock split.
• The company may need to transfer its listing to the Nasdaq Capital Market if it cannot regain compliance by November 18, 2024.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, reverse stock split, GOSS, stock price